Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Identification of immune-associated genes with altered expression in the spleen of mice enriched with probiotic Lactobacillus species using RNA-seq profiling
Publication Year: 2025 Source: Anim Biosci PMID: 39210803
No Abstract
Pharmacological Inhibition of N-Acylethanolamine Acid Amidase (NAAA) Mitigates Intestinal Fibrosis Through Modulation of Macrophage Activity
Publication Year: 2025 Source: J Crohns Colitis PMID: 39211986
BACKGROUND AND AIMS: Intestinal fibrosis, a frequent complication of inflammatory bowel disease, is characterized by stricture formation with no pharmacological treatment to date. N-acylethanolamine acid amidase (NAAA) is responsible for the hydrolysis of acylethanolamides (AEs, eg, palmitoylethanolamide and oleoylethanolamide). Here, we investigated NAAA and AE signaling in gut fibrosis. METHODS: …
Ulva lactuca polysaccharides combined with fecal microbiota transplantation ameliorated dextran sodium sulfate-induced colitis in C57BL/6J mice
Publication Year: 2025 Source: J Sci Food Agric PMID: 39212113
No Abstract
Integrin αVβ6: Autoantigen and Driver of Epithelial Remodeling in Colon and Bile Ducts in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
Publication Year: 2025 Source: J Crohns Colitis PMID: 39212221 DOI: 10.1093/ecco-jcc/jjae131
BACKGROUND: Recently, autoantibodies directed against the epithelial adhesion protein integrin alphaVbeta6 have been identified that are strongly associated with ulcerative colitis (UC). We aimed to elucidate whether anti-integrin alphaVbeta6 (anti-alphaVbeta6) is present in primary sclerosing cholangitis (PSC), its associated inflammatory bowel disease, or other cholestatic liver diseases and their persistence …
Making Sense of the COVID-19 Pandemic: The Use of Blogging by People with Inflammatory Bowel Disease
Publication Year: 2025 Source: Health Commun PMID: 39212234 DOI: 10.1080/10410236.2024.2394717
During the global COVID-19 pandemic one population that faced special challenges was individuals with preexisting chronic health conditions. In this study, we examined how people with inflammatory bowel disease (IBD) managed their autoimmune disease, considering their increased susceptibility to contracting COVID-19. Specifically, we analyzed how people with IBD made sense …
Eicosatetraynoic Acid Regulates Profibrotic Pathways in an Induced Pluripotent Stem Cell-Derived Macrophage-Human Intestinal Organoid Model of Crohn's Disease
Publication Year: 2025 Source: J Crohns Colitis PMID: 39212594
BACKGROUND AND AIMS: We previously identified small molecules predicted to reverse an ileal gene signature for future Crohn's Disease (CD) strictures. Here we used a new human intestinal organoid (HIO) model system containing macrophages to test a lead candidate, eicosatetraynoic acid (ETYA). METHODS: Induced pluripotent stem cell lines (iPSC) were …
External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn's disease
Publication Year: 2025 Source: Eur Radiol PMID: 39212672
No Abstract
Efficacy and Safety of Interleukin-12/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Publication Year: 2025 Source: Am J Ther PMID: 39212744
No Abstract
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials
Publication Year: 2025 Source: J Crohns Colitis PMID: 39212931
BACKGROUND: Endoscopic remission has emerged as an important treatment target in Crohn's disease (CD) and has been associated with improvement in long-term outcomes. We examined the relationship between achievement of endoscopic remission and hospitalizations using pooled data from 52-week Phase III maintenance trials of risankizumab and upadacitinib in patients with …
Potential interventions and interactions of bioactive polyphenols and functional polysaccharides to alleviate inflammatory bowel disease - A review
Publication Year: 2025 Source: Food Chem PMID: 39213975 DOI: 10.1016/j.foodchem.2024.140951
Inflammatory bowel disease is a multifaceted condition that is influenced by nutritional, microbial, environmental, genetic, psychological, and immunological factors. Polyphenols and polysaccharides have gained recognition for their therapeutic potential. This review emphasizes the biological effects of polyphenols and polysaccharides, and explores their antioxidant, anti-inflammatory, and microbiome-modulating properties in the management …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide